top of page

Search Results

이 사이트 검색

공란으로 548개 검색됨

  • FDA approves Contego Medical's Neuroguard IEP Direct system for carotid artery revascularisation

    Contego Medical has secured FDA premarket approval for its Neuroguard IEP Direct carotid revascularisation system alongside separate clearance for its embolic protection technology, advancing an integrated approach to stroke-risk reduction during carotid artery procedures. Contego Medical announced on 10 November 2026 that the US Food and Drug Administration had granted premarket approval for its Neuroguard IEP Direct system and separate 510(k) clearance for the Neuroguard IEP Embolic Protection System, supporting transcarotid artery revascularisation in selected patients with carotid artery stenosis. The technology combines flow reversal with an integrated embolic protection filter, while the supporting PERFORMANCE III study reported no strokes through 30 days among the studied patients; the underlying FDA premarket approval supplement decision was dated 4 November 2026, and the observed zero-stroke result should not be interpreted as a guarantee of procedural safety. Field Content Article Type Approvals Company Contego Medical Primary Device Neuroguard IEP Direct Additional Device Neuroguard IEP Embolic Protection System Announcement Date 10 November 2026 Underlying FDA Decision Date 4 November 2026 Regulatory Authority US Food and Drug Administration Primary Device Regulatory Pathway Premarket approval supplement Primary Device Regulatory Decision FDA approval Additional Device Regulatory Pathway 510(k) Additional Device Regulatory Decision FDA clearance Regulatory Market United States Device Category Carotid artery revascularisation and embolic protection Procedure Transcarotid artery revascularisation Procedure Abbreviation TCAR Target Patient Population Selected patients with carotid artery stenosis Clinical Condition Carotid artery stenosis Therapeutic Area Vascular medicine and stroke prevention Technology Component One Flow reversal Technology Component Two Integrated embolic protection filter Technology Objective Reduce cerebral embolisation risk during carotid revascularisation Supporting Clinical Study PERFORMANCE III Reported Stroke Outcome No strokes through 30 days in the studied population Reported 30-Day Stroke Rate 0% in the reported study population Study Population Size Not specified in supplied summary Long-Term Stroke Outcomes Not specified in supplied summary Regulatory Distinction FDA premarket approval and 510(k) clearance are different regulatory pathways Pharmaceutical Approval Involved No What Happened Contego Medical announced FDA approval for Neuroguard IEP Direct and separate clearance for an embolic protection system. Why It Matters The regulatory decisions support additional device options for carotid artery procedures where preventing cerebral embolisation is a major clinical objective. Clinical Significance The supporting study reported no strokes through 30 days, although this finding does not eliminate procedural risk. Regulatory Significance Establishes distinct FDA approval and clearance milestones for related carotid intervention technologies. Timing Clarification The FDA approval supplement decision was dated 4 November, while the company announced the milestones on 10 November 2026. Safety Clarification The observed 0% stroke rate is a study result rather than a guarantee for future patients. Key Takeaway Neuroguard IEP Direct received FDA approval, accompanied by separate clearance for Contego's embolic protection technology. What to Watch Clinical adoption, procedural outcomes, real-world stroke rates, longer-term safety and commercial availability. Submitted Source NeuroNews International Submitted Source URL https://neuronewsinternational.com/us-fda-approves-contego-medicals-neuroguard-iep-direct-system-for-tcar-integrated-embolic-protection/ Recommended Source Contego Medical announcement Recommended Source URL https://www.prweb.com/releases/contego-medical-receives-fda-approval-for-neuroguard-iep-direct-system-for-tcar-iep-302934443.html Relevant Date 10 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • NICE backs Padcev and Keytruda combination around surgery for muscle-invasive bladder cancer

    NICE has issued positive final draft guidance for perioperative Padcev and Keytruda in muscle-invasive bladder cancer, potentially expanding NHS treatment access before and after surgery for eligible patients regardless of cisplatin suitability. The UK's National Institute for Health and Care Excellence issued final draft guidance reported on 11 November 2026 recommending enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) before radical cystectomy, followed by treatment after surgery, for eligible adults with muscle-invasive bladder cancer in England and Wales. The recommendation applies irrespective of cisplatin eligibility and reflects NICE's assessment of clinical benefit and cost effectiveness, but remains at the final draft stage and concerns reimbursement and treatment access within an existing marketing authorisation rather than a new FDA or European Commission drug approval or an already implemented final NHS funding decision. Field Content Article Type Industry Updates Organisation National Institute for Health and Care Excellence Organisation Abbreviation NICE Country United Kingdom Relevant Health Systems England and Wales Announcement Reporting Date 11 November 2026 Decision Type Final draft technology appraisal guidance Recommendation Status Positive final draft recommendation Final Guidance Published Not confirmed in supplied summary Medicine One Padcev Medicine One Active Ingredient Enfortumab vedotin Medicine Two Keytruda Medicine Two Active Ingredient Pembrolizumab Treatment Regimen Enfortumab vedotin plus pembrolizumab Therapeutic Area Oncology Cancer Type Muscle-invasive bladder cancer Eligible Population Eligible adults with muscle-invasive bladder cancer Cisplatin Eligibility Restriction Recommendation applies regardless of cisplatin eligibility Treatment Timing Before and after surgery Neoadjuvant Treatment Combination therapy before radical cystectomy Surgical Procedure Radical cystectomy Adjuvant Treatment Treatment following surgery Treatment Strategy Perioperative systemic therapy Assessment Basis Clinical benefit and cost effectiveness Regulatory Context Within existing marketing authorisation New FDA Approval No New European Commission Approval No NHS Funding Implementation Not yet confirmed; guidance remains at final draft stage What Happened NICE issued positive final draft guidance supporting perioperative Padcev and Keytruda for eligible patients with muscle-invasive bladder cancer. Why It Matters The recommendation could broaden access to a treatment combination around surgery for patients with a serious bladder cancer diagnosis. Clinical Significance Supports consideration of combination systemic therapy in both neoadjuvant and adjuvant treatment settings. Health Policy Significance Represents a positive health technology assessment and potential reimbursement milestone in England and Wales. Regulatory Clarification A NICE recommendation concerns treatment access and reimbursement rather than granting marketing authorisation. Guidance Clarification Final draft guidance should not be described as completed implementation of an NHS funding decision. Key Takeaway NICE has backed perioperative enfortumab vedotin plus pembrolizumab at final draft stage for eligible adults with muscle-invasive bladder cancer. What to Watch Publication of final guidance, NHS implementation, patient eligibility criteria, treatment uptake and clinical outcomes. Primary Source PharmaTimes Primary Source URL https://pharmatimes.com/news/nice-backs-padcev-and-keytruda-combination/ Relevant Date 11 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Third Rock Ventures signs AI antibody discovery partnership with Funnel Biosciences worth up to $2.16 billion

    Third Rock Ventures has entered a potentially $2.16 billion AI-enabled antibody discovery collaboration with China's Funnel Biosciences, combining epitope-guided molecular design with multiple venture-selected drug targets. Funnel Biosciences announced a strategic research collaboration with Third Rock Ventures on 6 November 2026, subsequently reported on 9 November, under which the Beijing-based biotechnology company will apply its epitope-guided artificial intelligence antibody discovery platform to multiple drug targets nominated by the US venture capital firm. The agreement includes an undisclosed platform access fee and potential aggregate payments of approximately $2.16 billion subject to contractual conditions, while Funnel's combination of generative AI and physics-based molecular design is intended to support antibody discovery against challenging targets; the headline value represents contingent potential economics rather than guaranteed upfront consideration. Field Content Article Type Deals Research Partner Funnel Biosciences Strategic Partner Third Rock Ventures Deal Type Strategic research and AI antibody discovery collaboration Announcement Date 6 November 2026 Subsequent Industry Reporting 9 November 2026 Agreement Status Announced Research Partner Location Beijing, China Strategic Partner Location United States Technology Platform Epitope-guided AI antibody discovery Technology Components Generative artificial intelligence and physics-based molecular design Drug Discovery Modality Antibodies Research Objective Discover antibodies against challenging biological targets Target Selection Multiple drug targets nominated by Third Rock Ventures Specific Targets Not disclosed Therapeutic Indications Not disclosed Platform Access Fee Payable; amount not disclosed Maximum Potential Agreement Economics Approximately $2.16 billion Contingent Payment Structure Subject to contractual conditions Guaranteed Upfront Payment Not disclosed Milestone Categories Not specified in supplied summary Royalty Terms Not disclosed Number of Drug Targets Multiple; exact number not disclosed Development Stage Research and discovery Clinical Assets Transferred None specified Acquisition Involved No What Happened Third Rock Ventures entered a research collaboration with Funnel Biosciences to discover antibodies using an AI-enabled platform. Why It Matters The agreement illustrates substantial potential commercial value attached to AI-enabled antibody discovery capabilities. Strategic Significance Combines venture-selected therapeutic targets with computational antibody design and discovery technology. Financial Clarification The approximately $2.16 billion figure represents potential payments rather than guaranteed upfront consideration. Transaction Distinction Research collaboration rather than a company acquisition or regulatory approval. Key Takeaway Funnel Biosciences and Third Rock Ventures agreed to collaborate on AI-guided antibody discovery under a potentially multibillion-dollar arrangement. What to Watch Disclosure of nominated targets, discovery progress, programme advancement, contractual milestones and subsequent development partnerships. Submitted Source Endpoints News Submitted Source URL https://endpoints.news/third-rock-enters-2b-partnership-with-ai-focused-chinese-biotech/ Recommended Source VCBeat Health Recommended Source URL https://www.vcbeathealth.com/article/64181 Relevant Date 6 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • AstraZeneca acquires Omniose to expand bacterial conjugate vaccine technology

    AstraZeneca has completed its acquisition of US vaccine technology company Omniose, adding a proprietary bacterial bioconjugation platform to strengthen development of vaccines against serious infections and antimicrobial-resistant pathogens. AstraZeneca announced on 10 November 2026 that it had acquired Omniose as a wholly owned subsidiary within its infectious disease business, bringing in a bioconjugation technology designed to link bacterial polysaccharide antigens to carrier proteins through biological manufacturing processes. The acquisition builds on approximately three years of collaboration between the companies and expands AstraZeneca's capabilities in conjugate vaccine development for bacterial diseases and antimicrobial resistance, with financial terms undisclosed and no new vaccine regulatory approval associated with the transaction. Field Content Article Type Deals Acquirer AstraZeneca Acquired Company Omniose Deal Type Completed biotechnology company acquisition Announcement Date 10 November 2026 Transaction Status Completed Ownership Structure Wholly owned subsidiary of AstraZeneca Target Company Country United States Acquiring Business Area Infectious disease Acquired Technology Proprietary bacterial bioconjugation platform Technology Application Conjugate vaccine development Scientific Approach Biological linkage of bacterial polysaccharide antigens to carrier proteins Antigen Type Bacterial polysaccharides Carrier Component Carrier proteins Vaccine Modality Bacterial conjugate vaccines Therapeutic Area Infectious diseases Target Disease Category Serious bacterial infections Additional Strategic Focus Antimicrobial-resistant pathogens Prior Relationship Approximately three years of research collaboration Purchase Price Not disclosed Upfront Cash Consideration Not disclosed Contingent Consideration Not disclosed Total Transaction Value Not disclosed Development Assets Specific vaccine candidates not detailed in supplied summary Manufacturing Relevance Biological production of polysaccharide-protein conjugates New Vaccine Approval No What Happened AstraZeneca completed its acquisition of Omniose and its bacterial vaccine bioconjugation technology. Why It Matters The acquisition strengthens AstraZeneca's vaccine research capabilities in an area of continuing unmet need for bacterial infection prevention. Strategic Rationale Integrate a specialised bioconjugation platform into AstraZeneca's infectious disease research and development capabilities. Transaction Distinction Completed acquisition following an existing collaboration rather than a newly signed research agreement. Financial Clarification The companies did not disclose acquisition consideration. Key Takeaway AstraZeneca now owns Omniose and its bacterial conjugate vaccine technology platform. What to Watch Technology integration, vaccine pipeline expansion, candidate development and progress against antimicrobial-resistant pathogens. Submitted Source Fierce Biotech Submitted Source URL https://www.fiercebiotech.com/biotech/astrazeneca-buys-omniose-bacterial-vaccine-technology Recommended Source pharmaphorum Recommended Source URL https://pharmaphorum.com/news/az-boosts-vaccine-capabilities-omniose-buy Relevant Date 10 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA approves Merck KGaA's Pimjetmi for symptomatic tenosynovial giant cell tumour

    Merck KGaA's oral CSF1R inhibitor Pimjetmi has received FDA approval for adults with symptomatic tenosynovial giant cell tumour when surgery could cause substantial functional impairment, supported by a 56% response rate in the Phase III MANEUVER trial. The US Food and Drug Administration approved Pimjetmi (pimicotinib) on 10 November 2026 for adults with symptomatic tenosynovial giant cell tumour where surgical resection may cause worsening functional limitation or severe morbidity, providing a new oral treatment option from EMD Serono, the US healthcare business of Merck KGaA. In the Phase III MANEUVER trial, 56% of patients receiving pimicotinib achieved an objective response at Week 25 compared with 3.2% receiving placebo, alongside reported improvements in pain, joint mobility and physical function; the recommended dose is 50 mg orally once daily, with label warnings covering hepatotoxicity and embryo-fetal toxicity. Field Content Article Type Approvals Company Merck KGaA US Healthcare Business EMD Serono Product Pimjetmi Active Ingredient Pimicotinib Regulatory Authority US Food and Drug Administration Approval Date 10 November 2026 Approval Type FDA marketing approval Regulatory Status Approved in the United States for the specified symptomatic TGCT population Therapeutic Area Oncology and rare tumours Disease Tenosynovial giant cell tumour Disease Abbreviation TGCT Approved Population Adults with symptomatic TGCT for whom surgical resection may cause worsening functional limitation or severe morbidity Treatment Setting Symptomatic disease where surgery presents substantial functional or morbidity concerns Drug Class Oral kinase inhibitor Molecular Target Colony-stimulating factor 1 receptor Target Abbreviation CSF1R Administration Route Oral Recommended Dose 50 mg once daily Supporting Clinical Trial MANEUVER Clinical Trial Phase Phase III Primary Efficacy Measure Objective response rate at Week 25 Pimicotinib Response Rate 56% Placebo Response Rate 3.2% Additional Clinical Outcomes Reported improvements in pain, joint mobility and physical function Key Safety Warning One Hepatotoxicity Key Safety Warning Two Embryo-fetal toxicity Previous Regulatory Designations Earlier Fast Track and breakthrough therapy designations What Happened The FDA granted marketing approval to Pimjetmi for a defined adult population with symptomatic TGCT. Why It Matters The approval provides an oral treatment option for patients whose tumour location or surgical risks may make resection difficult. Clinical Significance The Phase III MANEUVER study demonstrated a substantially higher objective response rate than placebo at Week 25. Regulatory Clarification This is a new marketing approval rather than an orphan designation, Fast Track designation or breakthrough therapy designation. Key Takeaway Pimjetmi received FDA approval for symptomatic TGCT with a 56% reported objective response rate in its pivotal study. What to Watch Treatment adoption, liver safety monitoring, long-term efficacy, quality-of-life outcomes and reimbursement access. Primary Source US Food and Drug Administration Primary Source URL https://www.fda.gov/drugs/cancer-approvals/fda-approves-pimicotinib-symptomatic-tenosynovial-giant-cell-tumor Relevant Date 10 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Edesa Biotech licenses paridiprubart to Kyorin in Japan for up to $146 million plus royalties

    Edesa Biotech has licensed Japanese development and commercialisation rights to its investigational anti-TLR4 antibody paridiprubart to Kyorin Pharmaceutical in an agreement worth up to $146 million in stated payments plus royalties. Edesa Biotech and Kyorin Pharmaceutical announced an exclusive collaboration and licence agreement on 9 November 2026 granting Kyorin rights in Japan to develop and commercialise paridiprubart (EB05), an investigational monoclonal antibody targeting TLR4 for acute respiratory distress syndrome. The agreement includes a $12 million upfront payment, up to $134 million in development, reimbursement-listing and sales-related milestones and royalties on Japanese net sales, while Edesa retains rights outside Japan and manufacturing rights and the product remains investigational rather than approved for ARDS. Field Content Article Type Deals Licensor Edesa Biotech Licensee Kyorin Pharmaceutical Deal Type Exclusive regional collaboration and licence agreement Announcement Date 9 November 2026 Agreement Status Announced Licensed Product Paridiprubart Development Code EB05 Drug Modality Monoclonal antibody Molecular Target Toll-like receptor 4 Target Abbreviation TLR4 Therapeutic Area Critical care and inflammatory disease Target Indication Acute respiratory distress syndrome Indication Abbreviation ARDS Licensed Territory Japan Licensed Rights Japanese development and commercialisation Rights Retained by Edesa Rights outside Japan and manufacturing rights Upfront Payment $12 million Potential Milestone Payments Up to $134 million Milestone Categories Development, reimbursement listing and sales Maximum Stated Payments Up to $146 million Additional Royalties Royalties on Japanese net sales Royalty Rates Not disclosed Total Potential Economics Up to $146 million in stated payments plus royalties Regulatory Status Investigational; not approved for ARDS Development Stage Not specified in supplied summary Manufacturing Responsibilities Manufacturing rights retained by Edesa Commercial Responsibilities Kyorin holds Japanese commercialisation rights Geographic Scope Outside Japan Rights retained by Edesa What Happened Edesa granted Kyorin exclusive Japanese development and commercialisation rights to paridiprubart. Why It Matters The agreement provides a regional development and commercialisation partner for an investigational therapy targeting a serious critical-care condition. Strategic Significance Expands the potential Japanese development pathway for paridiprubart while preserving Edesa's rights in other markets. Financial Clarification The $146 million headline includes $134 million of contingent milestones; only $12 million is specified as upfront consideration, with royalties additional. Regulatory Clarification Paridiprubart remains investigational and the licensing agreement does not constitute marketing approval. Key Takeaway Kyorin obtained exclusive Japanese rights to paridiprubart through a $12 million upfront agreement with substantial contingent milestones. What to Watch Japanese development plans, clinical progress, regulatory interactions, milestone achievements and potential commercialisation. Primary Source Kyorin Pharmaceutical Primary Source URL https://www.kyorin-pharm.co.jp/en/news/2026/001956.shtml Relevant Date 9 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Abbott receives FDA approval and CE mark for UltiSynq conduction-system defibrillation lead

    Abbott has secured US FDA approval and European CE marking for its UltiSynq defibrillation lead, combining conduction-system pacing capabilities with implantable defibrillator therapy. Abbott announced on 10 November 2026 that the UltiSynq implantable cardioverter-defibrillator lead had received FDA approval and European CE marking, enabling left bundle branch area pacing alongside defibrillation therapy when used with compatible ICD or CRT-D systems. In the supporting ASCEND CSP investigational device study, implantation succeeded in 98.5% of 205 attempts, 86% of successfully implanted patients achieved confirmed or likely left bundle branch pacing, and the major complication-free rate at three months was 97.5%, supporting the device's regulatory milestones in the United States and Europe. Field Content Article Type Approvals Company Abbott Product UltiSynq Device Type Implantable cardioverter-defibrillator lead Announcement Date 10 November 2026 US Regulatory Authority US Food and Drug Administration US Regulatory Milestone FDA approval European Regulatory Milestone CE marking Regulatory Markets United States and Europe Device Application Conduction-system pacing and defibrillation therapy Pacing Approach Left bundle branch area pacing Pacing Abbreviation LBBAP Compatible System Types Implantable cardioverter-defibrillator and cardiac resynchronisation therapy defibrillator systems ICD Definition Implantable cardioverter-defibrillator CRT-D Definition Cardiac resynchronisation therapy defibrillator Therapeutic Area Cardiac electrophysiology Clinical Application Cardiac rhythm management Supporting Clinical Study ASCEND CSP Study Classification Investigational Device Exemption study Implantation Attempts 205 Implantation Success Rate 98.5% Confirmed or Likely Left Bundle Branch Pacing 86% among successfully implanted patients Major Complication-Free Rate 97.5% Safety Follow-Up Period Three months Device Innovation Integration of conduction-system pacing capability with defibrillation therapy Drug Approval Involved No Regulatory Distinction FDA approval and European CE marking are separate device regulatory milestones What Happened Abbott announced FDA approval and CE marking for its UltiSynq defibrillation lead. Why It Matters The device expands cardiac rhythm management options by supporting conduction-system pacing within compatible defibrillator systems. Clinical Significance The ASCEND CSP study reported high implantation success and a high major complication-free rate at three months. Regulatory Significance Establishes US and European regulatory milestones for the device. Key Takeaway UltiSynq has received FDA approval and CE marking following supportive investigational device study results. What to Watch Commercial availability, physician adoption, procedural experience, longer-term safety and clinical outcomes. Primary Source Abbott Primary Source URL https://abbott.mediaroom.com/press-releases?item=124791 Relevant Date 10 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Brazil approves Henlius and Organon's pertuzumab biosimilar for HER2-positive breast cancer

    Brazil's health regulator has approved Henlius and Organon's pertuzumab biosimilar for certain HER2-positive breast cancer patients, marking the country's first authorisation of a biosimilar to this established oncology antibody. Henlius and Organon announced on 9 November 2026 that Brazil's National Health Surveillance Agency, Anvisa, had granted marketing authorisation for their pertuzumab biosimilar for specified HER2-positive breast cancer indications, supported by analytical, pharmacokinetic and comparative clinical evidence demonstrating biosimilarity to the reference medicine. The Brazilian decision follows earlier US FDA approval in November 2025 and European Commission authorisation in April 2026, with Brazil and European commercial launches planned for 2027 under an existing Genentech settlement and licence agreement, making this a new country-specific approval rather than a new US or EU authorisation or immediate product launch. Field Content Article Type Approvals Developer Henlius Commercial Partner Organon Product Pertuzumab biosimilar Active Ingredient Pertuzumab Regulatory Authority Brazilian Health Regulatory Agency Regulatory Authority Name Anvisa Country Brazil Announcement Date 9 November 2026 Approval Type Marketing authorisation Regulatory Status Approved in Brazil for specified HER2-positive breast cancer indications First-in-Market Status First pertuzumab biosimilar approved in Brazil Therapeutic Area Oncology Cancer Type HER2-positive breast cancer Biologic Class Monoclonal antibody biosimilar Molecular Target HER2 Reference Product Originator pertuzumab Evidence Package Analytical, pharmacokinetic and comparative clinical evidence Biosimilarity Finding Evidence supported biosimilarity to the reference biologic Developer Responsibilities Product development Commercial Partner Responsibilities Commercialisation under the existing licensing arrangement Prior US Regulatory Approval November 2025 Prior European Commission Authorisation April 2026 Planned Brazil Launch 2027 Planned European Launch 2027 Relevant Commercial Agreement Existing Genentech settlement and licence agreement Immediate Commercial Launch No; launch is planned for 2027 New US Approval No New EU Approval No What Happened Anvisa granted Brazilian marketing authorisation for Henlius and Organon's pertuzumab biosimilar. Why It Matters The approval introduces a biosimilar regulatory option for HER2-positive breast cancer in Brazil, potentially supporting future competition and treatment access. Regulatory Significance Establishes the first Brazilian authorisation of a pertuzumab biosimilar. Commercial Significance Creates a regulatory foundation for a planned Brazilian launch in 2027. Key Takeaway Henlius and Organon secured a new Brazilian biosimilar approval for pertuzumab, distinct from previously granted US and EU authorisations. What to Watch Brazilian commercial launch, pricing, reimbursement, oncology adoption and implementation of existing licensing arrangements. Primary Source Henlius Primary Source URL https://www.henlius.com/en/newsd/0/31698.html?title=New-biosimilar-for-patients-with-certain-HER2-positive-breast-cancer-is-approved-by-Anvisa Relevant Date 9 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • argenx agrees to acquire Unnatural Products for up to $1.15 billion to expand peptide drug discovery

    argenx has agreed to acquire macrocyclic peptide specialist Unnatural Products in a transaction worth up to $1.15 billion, combining a substantial upfront payment with development-dependent milestones to expand beyond antibody therapeutics. The definitive agreement announced on 9 November 2026 provides for argenx to acquire the remaining shares of Unnatural Products for $550 million in upfront cash and up to $595 million in contingent development and regulatory milestones, following more than two years of collaboration and argenx's existing minority investment. The acquisition would add Unnatural Products' macrocyclic peptide discovery capabilities to argenx's antibody engineering platform, supporting potential oral and long-acting immunology medicines, while completion is expected by year-end 2026 subject to customary conditions and the headline $1.15 billion represents maximum potential rather than guaranteed consideration. Field Content Article Type Deals Acquirer argenx Target Company Unnatural Products Deal Type Definitive acquisition agreement Announcement Date 9 November 2026 Transaction Status Announced; not yet completed Maximum Potential Transaction Value Approximately $1.15 billion Upfront Cash Consideration $550 million Contingent Milestone Consideration Up to $595 million Milestone Categories Development and regulatory milestones Milestone Payment Status Contingent on future achievements Existing Ownership argenx already holds a minority stake Acquisition Scope Remaining shares of Unnatural Products Prior Relationship Research collaboration lasting more than two years Target Technology Macrocyclic peptide discovery platform Drug Discovery Modality Macrocyclic peptides Potential Product Characteristics Oral and long-acting therapeutic candidates Therapeutic Focus Immunology Acquirer Existing Technology Antibody engineering capabilities Strategic Objective Expand therapeutic discovery capabilities beyond antibody-based medicines Technology Integration Combine macrocyclic peptide discovery with argenx's existing therapeutic development expertise Expected Closing By year-end 2026 Closing Conditions Customary transaction closing conditions Regulatory Approval Status No new medicine approval associated with the transaction What Happened argenx agreed to acquire Unnatural Products for upfront cash and contingent milestone payments. Why It Matters The transaction provides argenx with a complementary discovery platform that could support new immunology medicines with differentiated administration profiles. Strategic Significance Expands argenx's drug discovery capabilities into macrocyclic peptides while building on an established collaboration. Financial Clarification The $1.15 billion maximum includes $595 million of contingent milestones; only $550 million is specified as upfront cash. Transaction Distinction Definitive agreement rather than a completed acquisition Key Takeaway argenx is pursuing a major peptide technology acquisition with $550 million upfront and substantial performance-dependent consideration. What to Watch Transaction completion, platform integration, new peptide candidates, clinical development milestones and future milestone payments. Primary Source argenx Primary Source URL https://argenx.com/news/2026/press-release-3398049 Relevant Date 9 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA approves Bayer's Sunharbo as first factor XIa inhibitor for secondary stroke prevention

    Bayer's first-in-class factor XIa inhibitor has secured FDA approval for secondary stroke prevention, offering a new antithrombotic approach alongside antiplatelet therapy for selected high-risk adults. The US Food and Drug Administration approved Bayer's Sunharbo (asundexian) 50 mg tablets on 9 November 2026 for use with antiplatelet therapy to reduce stroke risk in adults following a recent mild-to-moderate non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack, making it the first FDA-approved factor XIa inhibitor. The decision was supported by the Phase III OCEANIC-STROKE trial, which demonstrated a 26% relative reduction in ischaemic stroke compared with antiplatelet therapy alone and similar overall rates of ISTH major bleeding, establishing a new treatment option for a specifically defined secondary-prevention population rather than general stroke prevention. Field Content Article Type Approvals Company Bayer Product Sunharbo Active Ingredient Asundexian Regulatory Authority US Food and Drug Administration Approval Date 9 November 2026 Approval Type FDA marketing approval Regulatory Status Approved in the United States for the specified secondary stroke prevention indication First-in-Class Status First FDA-approved factor XIa inhibitor Therapeutic Area Cardiovascular and cerebrovascular medicine Treatment Objective Secondary stroke prevention Approved Indication Reduce stroke risk in adults following recent mild-to-moderate non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack Eligible Population Adults meeting the specified recent stroke or high-risk transient ischaemic attack criteria Stroke Subtype Non-cardioembolic ischaemic stroke Additional Eligible Condition High-risk transient ischaemic attack Dosage Form Oral tablets Approved Strength 50 mg Combination Treatment Antiplatelet therapy Drug Class Factor XIa inhibitor Molecular Target Activated coagulation factor XI Mechanism of Action Inhibition of factor XIa within the coagulation pathway Supporting Clinical Trial OCEANIC-STROKE Clinical Trial Phase Phase III Comparator Antiplatelet therapy alone Reported Efficacy Result 26% relative reduction in ischaemic stroke Bleeding Safety Finding Similar overall rates of ISTH major bleeding between treatment groups Bleeding Definition International Society on Thrombosis and Haemostasis major bleeding Absolute Risk Reduction Not specified in supplied summary Trial Population Size Not specified in supplied summary What Happened The FDA approved Sunharbo as the first factor XIa inhibitor for secondary stroke prevention in a defined adult population. Why It Matters The approval introduces a new anticoagulant mechanism to complement antiplatelet therapy for selected patients at risk of recurrent stroke. Clinical Significance Phase III evidence demonstrated a relative reduction in ischaemic stroke without an apparent increase in overall ISTH major bleeding rates. Regulatory Clarification The approval applies to the specified secondary-prevention population and combination regimen rather than general stroke prevention. Key Takeaway Sunharbo establishes factor XIa inhibition as an FDA-approved therapeutic approach for selected adults following non-cardioembolic stroke or high-risk TIA. What to Watch Clinical adoption, prescribing guidance, bleeding safety surveillance, reimbursement and additional factor XIa inhibitor development. Primary Source US Food and Drug Administration Primary Source URL https://www.fda.gov/news-events/press-announcements/fda-approves-first-factor-xla-inhibitor-help-prevent-stroke-certain-adults-high-risk Relevant Date 9 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Abeona acquires Phase III-ready ABO-801 drug assets from Ellodi in transaction worth up to $80 million plus royalties

    Abeona Therapeutics has acquired the Phase III-ready eosinophilic oesophagitis candidate ABO-801 from Ellodi Pharmaceuticals in a share-based asset transaction with regulatory and commercial milestones, alongside a separate $30 million financing agreement. Abeona announced on 9 November 2026 that it had completed the acquisition of Ellodi Pharmaceuticals' APT-1011 programme, renamed ABO-801, an orally disintegrating fluticasone propionate formulation being developed for eosinophilic oesophagitis, in exchange for $20 million of Abeona shares issued at closing and contingent payments tied to future regulatory and commercial achievements. The transaction includes $30 million payable upon FDA approval, up to $30 million in sales milestones and low-to-mid-teen royalties, while Abeona's separately announced $30 million private placement provides financing rather than acquisition consideration and ABO-801's existing orphan and Fast Track designations do not constitute a new drug approval. Field Content Article Type Deals Acquirer Abeona Therapeutics Seller Ellodi Pharmaceuticals Deal Type Completed therapeutic asset acquisition Announcement Date 9 November 2026 Transaction Status Completed Acquired Programme ABO-801 Former Programme Name APT-1011 Active Ingredient Fluticasone propionate Drug Formulation Orally disintegrating formulation Therapeutic Area Gastroenterology Target Indication Eosinophilic oesophagitis Development Stage Phase III-ready Total Specified Fixed and Contingent Consideration Up to $80 million excluding royalties Consideration Paid at Closing $20 million in Abeona shares Upfront Cash Consideration None FDA Approval Milestone $30 million contingent on FDA approval Sales Milestones Up to $30 million Additional Royalty Consideration Low-to-mid-teen royalties Royalty Base and Duration Not specified in supplied summary Existing Orphan Drug Status Previously designated Existing Fast Track Status Previously designated New FDA Marketing Approval No Separate Financing Transaction $30 million private placement agreement Private Placement Purpose Corporate financing Private Placement Classification Not acquisition consideration Acquired Rights ABO-801 development assets Next Development Step Potential Phase III clinical development What Happened Abeona completed an asset acquisition of the Phase III-ready ABO-801 programme from Ellodi Pharmaceuticals. Why It Matters The transaction adds a late-stage gastrointestinal drug candidate to Abeona's development portfolio. Strategic Significance Expands Abeona's pipeline through a transaction structured around equity consideration and future product milestones. Financial Clarification The $80 million potential consideration comprises $20 million in shares and up to $60 million in milestones, excluding royalties; the separate $30 million financing is not part of the purchase price. Regulatory Clarification Existing orphan and Fast Track designations do not indicate FDA marketing approval. Key Takeaway Abeona acquired ABO-801 without upfront cash, with future payments dependent on approval and sales performance. What to Watch Phase III trial plans, regulatory interactions, financing completion, FDA review and milestone achievement. Primary Source Abeona Therapeutics SEC-filed announcement Primary Source URL https://www.sec.gov/Archives/edgar/data/318306/000149315226050606/ex99-1.htm Relevant Date 9 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • China approves Bio-Thera's Ashuli as its first golimumab biosimilar

    Bio-Thera has secured Chinese regulatory approval for Ashuli, the country's first golimumab biosimilar, expanding domestic biosimilar competition in rheumatoid arthritis and ankylosing spondylitis. Bio-Thera announced on 6 November 2026 that China's National Medical Products Administration had approved BAT2506, marketed as Ashuli, for rheumatoid arthritis and ankylosing spondylitis, establishing the first approved golimumab biosimilar in China. The TNF-alpha-targeting monoclonal antibody becomes Bio-Thera's sixth approved biosimilar in its domestic market and represents a new China-specific regulatory milestone, separate from earlier international authorisations and from the company's previously reported BAT2306 secukinumab biosimilar approval. Field Content Article Type Approvals Company Bio-Thera Solutions Product Brand Ashuli Development Code BAT2506 Active Ingredient Golimumab Product Type Biosimilar monoclonal antibody Reference Biologic Golimumab reference product Molecular Target Tumour necrosis factor alpha Target Abbreviation TNF-alpha Regulatory Authority National Medical Products Administration Regulatory Authority Abbreviation NMPA Country China Announcement Date 6 November 2026 Approval Type Marketing authorisation Regulatory Status Approved in China First-in-Market Status First golimumab biosimilar approved in China Approved Indication One Rheumatoid arthritis Approved Indication Two Ankylosing spondylitis Therapeutic Area Immunology and inflammatory diseases Biosimilar Portfolio Milestone Bio-Thera's sixth approved biosimilar in China International Regulatory Context Separate earlier approvals in other markets under different brand names Domestic Commercial Launch Date Not specified in supplied summary Comparative Clinical Evidence Not detailed in supplied summary Mechanism of Action TNF-alpha inhibition Previous Distinct Bio-Thera Approval BAT2306 secukinumab biosimilar Previous Approval Timing October 2026 Relationship to BAT2306 Different active ingredient, reference biologic and regulatory event What Happened China's NMPA approved Bio-Thera's BAT2506 golimumab biosimilar under the Ashuli brand. Why It Matters The approval creates a new domestic biosimilar option targeting TNF-alpha-mediated inflammatory diseases. Regulatory Significance Marks China's first approval of a golimumab biosimilar. Commercial Significance Expands Bio-Thera's approved biosimilar portfolio and potential domestic market opportunities. Key Takeaway Ashuli is now authorised in China for rheumatoid arthritis and ankylosing spondylitis. What to Watch Commercial launch, pricing, reimbursement, hospital adoption and competitive developments in the Chinese TNF-alpha inhibitor market. Primary Source Bio-Thera Solutions Primary Source URL https://www.prnewswire.com/news-releases/bio-thera-announces-nmpa-approval-of-bat2506-the-first-golimumab-biosimilar-approved-in-china-302931732.html Relevant Date 6 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

bottom of page